Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasm Metastasis 2Uveal Melanoma 1Sarcoma 1Rhabdomyosarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Neoplasms 1Mesothelioma 1Melanoma 1Medulloblastoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasms × LY2940680 × Clear all
NCT01226485 2019-09-13

A Study in Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
84 enrolled 22 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡